Indications
Meropenem is approved for use as a monotherapy in the management of various infections, provided they are caused by susceptible strains of specific microorganisms. It is indicated for the treatment of complicated skin and skin structure infections associated with Staphylococcus aureus (both beta-lactamase-producing and non-beta-lactamase-producing methicillin-susceptible isolates), Streptococcus pyogenes, Streptococcus agalactiae, viridans group streptococci, and Enterococcus faecalis (excluding vancomycin-resistant strains). Additionally, it is effective against infections caused by Pseudomonas aeruginosa, Escherichia coli, Proteus mirabilis, Bacteroides fragilis, and Peptostreptococcus species. Meropenem is also indicated for the treatment of complicated appendicitis and peritonitis caused by organisms such as viridans group streptococci, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Bacteroides fragilis, Bacteroides thetaiotaomicron, and Peptostreptococcus species. Furthermore, it is utilized in the treatment of bacterial meningitis due to Streptococcus pneumoniae, Haemophilus influenzae (both beta-lactamase-producing and non-beta-lactamase-producing isolates), and Neisseria meningitidis.
Pharmacodynamics
Meropenem functions as a broad-spectrum carbapenem antibiotic with efficacy against both Gram-positive and Gram-negative bacteria. It exerts its antibacterial effects by efficiently penetrating bacterial cells and disrupting the synthesis of essential cell wall components. This disruption results in bacterial cell death, thereby eliminating the infection.
Metabolism
Meropenem is predominantly excreted unchanged from the body. It undergoes minimal metabolic transformation, producing a single metabolite that is microbiologically inactive. This characteristic facilitates its efficient elimination while maintaining its therapeutic effectiveness.
Mechanism of Action
Meropenem exhibits bactericidal properties by inhibiting cell wall synthesis. It efficiently penetrates the cell walls of both Gram-positive and Gram-negative bacteria, reaching critical penicillin-binding protein (PBP) targets. The drug demonstrates its strongest affinities for PBPs 2, 3, and 4 in Escherichia coli and Pseudomonas aeruginosa, as well as PBPs 1, 2, and 4 in Staphylococcus aureus.
